Filing Flows › Comparisons › LENZ vs ALGS
Lenz Therapeutics vs Aligos Therapeutics: LENZ and ALGS compared
Lenz Therapeutics is the larger company: $3.4M of revenue in its latest quarter (Q3 2026) against $2.8M for Aligos Therapeutics (Q3 2026). Aligos Therapeutics is growing faster (+282% against -73% a year earlier). Aligos Therapeutics is more profitable, with an operating margin of -773.5% against -972.8%.
Where the money goes: LENZ and ALGS
Lenz Therapeutics (LENZ) · Q3 2026
Lenz Therapeutics, Q3 2026: revenue $3.4M (-73% year over year), operating margin -972.8%, net loss $31.0M, operating cash flow −$22.3M. The chart follows the revenue to costs, profit and cash.
Aligos Therapeutics (ALGS) · Q3 2026
Aligos Therapeutics, Q3 2026: revenue $2.8M (+282% year over year), operating margin -773.5%, net loss $21.9M, operating cash flow $1.5M. The chart follows the revenue to costs, profit and cash.
| Lenz Therapeutics (LENZ) | Aligos Therapeutics (ALGS) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $3.4M | $2.8M |
| Revenue growth, Y/Y | -73% | +282% |
| Operating margin | -972.8% | -773.5% |
| Net earnings | −$31.0M | −$21.9M |
| Net margin | -915.2% | -772.4% |
| Operating cash flow | −$22.3M | $1.5M |
| Market value | — | $55.7M |
| Analysts’ mean target | — | $52.38 |
Where the revenue comes from
Lenz Therapeutics
- Product sales, net: $2.6M (77%)
- License revenue: $785K (23%)
Questions
Which is bigger, Lenz Therapeutics or Aligos Therapeutics?
Lenz Therapeutics is the larger company: $3.4M of revenue in its latest quarter (Q3 2026) against $2.8M for Aligos Therapeutics (Q3 2026).
Is Lenz Therapeutics or Aligos Therapeutics growing faster?
Aligos Therapeutics is growing faster (+282% against -73% a year earlier).
Which is more profitable, Lenz Therapeutics or Aligos Therapeutics?
Aligos Therapeutics is more profitable, with an operating margin of -773.5% against -972.8%.
More: Lenz Therapeutics earnings · how Lenz Therapeutics makes money · Aligos Therapeutics earnings · how Aligos Therapeutics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 3, 2026; 10-Q filed Nov 6, 2026). Fiscal quarters can end on different dates. Not investment advice.